Paladin Labs Inc operates in the Pharmaceutical preparations sector. Paladin Labs Inc. is a specialty pharmaceutical company focused on developing, acquiring, in-licensing, marketing and distributing pharmaceutical products. Tridural is a once-a-day tramadol product indicated as a first-line therapy for adults with moderate pain requiring several days or more of treatment. Abstral is a sublingual (under the tongue) formulation of fentanyl, an opioid used for the management of breakthrough pain for cancer patients already receiving opioid analgesics for chronic pain. Trelstar is an injectable, luteinizing hormone releasing hormone agonist indicated for the palliative treatment of prostate cancer and endometriosis. It has operations in Canada, Barbados, the United States, Europe, Australia and New Zealand. As of December 31, 2010, it owned 14% interest in Isotechnika Pharma Inc. On November 1, 2010, it acquired the Canadian license for Metadol. In July 2010, a generic version of Pennsaid was approved in Canada. In October 2011, it acquired Labopharm Inc. In our complete report available for purchase the company is compared to: AEterna Zentaris Incorporated, Afexa Life Sciences Incorporated and Cardiome Pharma Corp..